CA2818249C - Pharmaceutical compositions comprising radezolid, hydroxypropylmethyl cellulose polymer, and a physical mixture - Google Patents

Pharmaceutical compositions comprising radezolid, hydroxypropylmethyl cellulose polymer, and a physical mixture Download PDF

Info

Publication number
CA2818249C
CA2818249C CA2818249A CA2818249A CA2818249C CA 2818249 C CA2818249 C CA 2818249C CA 2818249 A CA2818249 A CA 2818249A CA 2818249 A CA2818249 A CA 2818249A CA 2818249 C CA2818249 C CA 2818249C
Authority
CA
Canada
Prior art keywords
pharmaceutical composition
patient
composition according
microbial infection
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2818249A
Other languages
English (en)
French (fr)
Other versions
CA2818249A1 (en
Inventor
Danping Li
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Melinta Subsidiary Corp
Original Assignee
Melinta Subsidiary Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Melinta Subsidiary Corp filed Critical Melinta Subsidiary Corp
Publication of CA2818249A1 publication Critical patent/CA2818249A1/en
Application granted granted Critical
Publication of CA2818249C publication Critical patent/CA2818249C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2818249A 2010-11-24 2011-11-21 Pharmaceutical compositions comprising radezolid, hydroxypropylmethyl cellulose polymer, and a physical mixture Active CA2818249C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41680710P 2010-11-24 2010-11-24
US61/416,807 2010-11-24
PCT/US2011/061643 WO2012071324A2 (en) 2010-11-24 2011-11-21 Pharmaceutical compositions

Publications (2)

Publication Number Publication Date
CA2818249A1 CA2818249A1 (en) 2012-05-31
CA2818249C true CA2818249C (en) 2021-04-13

Family

ID=46146374

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2818249A Active CA2818249C (en) 2010-11-24 2011-11-21 Pharmaceutical compositions comprising radezolid, hydroxypropylmethyl cellulose polymer, and a physical mixture

Country Status (21)

Country Link
US (2) US20140088164A1 (enExample)
EP (1) EP2642996B1 (enExample)
JP (2) JP6370550B2 (enExample)
KR (1) KR101944124B1 (enExample)
CN (1) CN103391778B (enExample)
AU (1) AU2011332031B2 (enExample)
BR (1) BR112013012833A8 (enExample)
CA (1) CA2818249C (enExample)
EA (1) EA027791B1 (enExample)
ES (1) ES2836809T3 (enExample)
HU (1) HUE052801T2 (enExample)
IL (1) IL226378A0 (enExample)
MX (1) MX350565B (enExample)
MY (2) MY171941A (enExample)
NZ (1) NZ610638A (enExample)
PH (1) PH12013501069A1 (enExample)
PT (1) PT2642996T (enExample)
SG (2) SG10201509530YA (enExample)
UA (1) UA113722C2 (enExample)
WO (1) WO2012071324A2 (enExample)
ZA (1) ZA201303732B (enExample)

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5688792A (en) 1994-08-16 1997-11-18 Pharmacia & Upjohn Company Substituted oxazine and thiazine oxazolidinone antimicrobials
US5895663A (en) 1997-07-31 1999-04-20 L. Perrigo Company Pseudoephedrine hydrochloride extended-release tablets
US6451345B1 (en) * 2000-01-20 2002-09-17 Eurand Pharmaceuticals Ltd. Functional coating of linezolid microcapsules for taste-masking and associated formulation for oral administration
AR028253A1 (es) * 2000-03-16 2003-04-30 Pfizer Prod Inc Inhibidores de la glucogeno fosforilasa
PE20011088A1 (es) * 2000-03-22 2001-10-04 Upjohn Co Tratamiento de infecciones del tracto urinario con oxazolidinonas antibacterianas
EP1265608B1 (en) * 2000-03-22 2008-10-29 Pharmacia & Upjohn Company LLC Oxazolidinone tablet formulation
NZ522990A (en) 2000-06-05 2003-08-29 Dong A Pharm Novel oxazolidinone derivatives and a process for the preparation thereof
AU2001267011B2 (en) * 2000-06-21 2006-02-02 Cubist Pharmaceuticals, Inc. Compositions and methods to improve the oral absorption of antimicrobial agents
PL362979A1 (en) 2000-12-11 2004-11-02 Takeda Chemical Industries, Ltd. Medicinal compositions improved in solublity in water
JP2002241268A (ja) * 2000-12-11 2002-08-28 Takeda Chem Ind Ltd 水溶解性が改善された医薬組成物
TWI378092B (en) 2003-06-03 2012-12-01 Rib X Pharmaceuticals Inc Biaryl heterocyclic compounds and methods of making and using the same
JP2007514782A (ja) 2003-12-17 2007-06-07 リブ−エックス ファーマシューティカルズ，インコーポレイテッド ハロゲン化ビアリール複素環式化合物ならびにその作製方法および使用方法
KR100854211B1 (ko) 2003-12-18 2008-08-26 동아제약주식회사 신규한 옥사졸리디논 유도체, 그의 제조방법 및 이를유효성분으로 하는 항생제용 약학 조성물
TW200534879A (en) * 2004-03-25 2005-11-01 Bristol Myers Squibb Co Coated tablet formulation and method
NZ580951A (en) * 2005-04-29 2011-06-30 Cubist Pharm Inc Therapeutic compositions
EP1912730A2 (en) 2005-07-28 2008-04-23 Isp Investments Inc. Method to improve characteristics of spray dried powders and granulated materials, and the products thereby produced
EP1909763A2 (en) 2005-07-28 2008-04-16 Isp Investments Inc. Benzoquinones of enhanced bioavailability
US20070104785A1 (en) * 2005-07-29 2007-05-10 Navale Suryakant V Tablets of linezolid form iii and processes for their preparation
CN101378731B (zh) * 2006-02-09 2014-03-05 默沙东公司 Cetp抑制剂的聚合物制剂
UY30535A1 (es) * 2006-08-10 2008-03-31 Cipla Ltd Composicion comprendiendo farmacos antirretrovirales y al menos un polimero insoluble en agua, proceso de preparacion y aplicaciones.
US20120208857A1 (en) * 2009-10-13 2012-08-16 Burak Eric S Pharmaceutical Compositions
WO2011159626A1 (en) * 2010-06-14 2011-12-22 Bend Research, Inc. Hydroxypropyl methyl cellulose acetate succinate with enhanced acetate and succinate substitution
WO2012061360A2 (en) * 2010-11-01 2012-05-10 Rib-X Pharmaceuticals, Inc. Pharmaceutical compositions

Also Published As

Publication number Publication date
ES2836809T3 (es) 2021-06-28
JP6370550B2 (ja) 2018-08-08
HUE052801T2 (hu) 2021-05-28
MX350565B (es) 2017-09-11
US20160374995A1 (en) 2016-12-29
BR112013012833A8 (pt) 2018-01-02
CN103391778B (zh) 2016-04-20
EP2642996A4 (en) 2014-05-21
MY171941A (en) 2019-11-08
ZA201303732B (en) 2018-12-19
MY182136A (en) 2021-01-18
NZ610638A (en) 2015-05-29
PT2642996T (pt) 2020-12-30
AU2011332031A1 (en) 2013-06-06
WO2012071324A3 (en) 2012-08-16
KR20140033314A (ko) 2014-03-18
EP2642996B1 (en) 2020-09-23
WO2012071324A2 (en) 2012-05-31
MX2013005813A (es) 2013-09-13
BR112013012833A2 (pt) 2016-08-23
CA2818249A1 (en) 2012-05-31
SG190354A1 (en) 2013-06-28
JP2013543893A (ja) 2013-12-09
EA201390764A1 (ru) 2013-09-30
US20140088164A1 (en) 2014-03-27
PH12013501069A1 (en) 2013-07-08
SG10201509530YA (en) 2015-12-30
UA113722C2 (uk) 2017-03-10
CN103391778A (zh) 2013-11-13
IL226378A0 (en) 2013-07-31
EA027791B1 (ru) 2017-09-29
KR101944124B1 (ko) 2019-01-30
JP2017081950A (ja) 2017-05-18
US10300046B2 (en) 2019-05-28
EP2642996A2 (en) 2013-10-02
AU2011332031B2 (en) 2017-01-12

Similar Documents

Publication Publication Date Title
US20030147957A1 (en) Dual release formulation comprising levodopa ethyl ester and a decarboxylase inhibitor in immediate release layer with levodopa ethyl ester and a decarboxylase inhibitor in a controlled release core
AU2016234893A1 (en) Pharmaceutical Compositions
US10300046B2 (en) Pharmaceutical compositions
US20200237744A1 (en) Antimicrobial Compositions with Effervescent Agents
HK1230972A (en) Pharmaceutical compositions comprising radezolid
HK1230972A1 (en) Pharmaceutical compositions comprising radezolid
HK40065457A (en) Antimicrobial compositions with effervescent agents
HK40020067B (en) Antimicrobial compositions with effervescent agents
HK40020067A (en) Antimicrobial compositions with effervescent agents
HK1236006B (en) Antimicrobial compositions with effervescent agents

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20161118